A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients with Psoriasis

NCT06620692 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: 5% GM-XANTHO [GM-XAN003]
DRUG: Placebo

Sponsor

Xantho Biotechnology Co., LTD

Collaborators

[object Object]